OBJECTIVES: To assess the efficacy and safety of rituximab (RTX) in patients with Takayasu arteritis (TAK). METHODS: We conducted a retrospective study on seven TAK patients treated with RTX. Six of the seven patients had a disease refractory to high dose glucocorticoids and conventional immunosuppressive and/or biologic agents. One newly diagnosed, treatment-naïve TAK patient refused glucocorticoids and received RTX alone. Clinical evaluation, laboratory tests and imaging modalities (CT or MR-angiography, and 18 F-fluorodeoxyglucose PET/CT) were performed at first RTX administration and every 6 months thereafter. Disease activity was assessed using the Kerr index. We also performed a literature review using PubMed, Ovid MEDLINE and Cochrane library. RESULTS: Seven patients (6 females) were included in the study. Mean ( s . d .) age was 32.4 (17.3) years. At first RTX administration, all patients had active disease according to the Kerr index (⩾2), and had also evidence of active disease at PET/CT. Despite RTX treatment, four of the seven patients had evidence of persistent disease activity and/or radiographic disease progression during follow-up. Three out of seven patients in whom RTX was employed as rescue therapy achieved complete remission. In the literature review, we identified five papers describing nine patients treated with RTX with good results in eight cases, but short follow-up. CONCLUSION: Our data do not support a role for RTX as first line biologic therapy in TAK patients, but it may have a role in some patients as second or third line biologic therapy.

Objectives. To assess the efficacy and safety of rituximab (RTX) in patients with Takayasu arteritis (TAK). Methods. We conducted a retrospective study on seven TAK patients treated with RTX. Six of the seven patients had a disease refractory to high dose glucocorticoids and conventional immunosuppressive and/ or biologic agents. One newly diagnosed, treatment-naïve TAK patient refused glucocorticoids and received RTX alone. Clinical evaluation, laboratory tests and imaging modalities (CT or MR-angiography, and 18F-fluorodeoxyglucose PET/CT) were performed at first RTX administration and every 6 months thereafter. Disease activity was assessed using the Kerr index. We also performed a literature review using PubMed, Ovid MEDLINE and Cochrane library. Results. Seven patients (6 females) were included in the study. Mean (S.D.) age was 32.4 (17.3) years. At first RTX administration, all patients had active disease according to the Kerr index (≥), and had also evidence of active disease at PET/CT. Despite RTX treatment, four of the seven patients had evidence of persistent disease activity and/or radiographic disease progression during follow-up. Three out of seven patients in whom RTX was employed as rescue therapy achieved complete remission. In the literature review, we identified five papers describing nine patients treated with RTX with good results in eight cases, but short follow-up. Conclusion. Our data do not support a role for RTX as first line biologic therapy in TAK patients, but it may have a role in some patients as second or third line biologic therapy.

Rituximab therapy for Takayasu arteritis: A seven patients experience and a review of the literature / Pazzola, Giulia; Muratore, Francesco; Pipitone, Nicolò; Crescentini, Filippo; Cacoub, Patrice; Boiardi, Luigi; Spaggiari, Lucia; Comarmond, Cloe; Croci, Stefania; Saadoun, David; Salvarani, Carlo. - In: RHEUMATOLOGY. - ISSN 1462-0332. - 57:7(2018), pp. 1151-1155. [10.1093/rheumatology/kex249]

Rituximab therapy for Takayasu arteritis: A seven patients experience and a review of the literature

Pazzola, Giulia;Muratore, Francesco;Crescentini, Filippo;Salvarani, Carlo
2018

Abstract

Objectives. To assess the efficacy and safety of rituximab (RTX) in patients with Takayasu arteritis (TAK). Methods. We conducted a retrospective study on seven TAK patients treated with RTX. Six of the seven patients had a disease refractory to high dose glucocorticoids and conventional immunosuppressive and/ or biologic agents. One newly diagnosed, treatment-naïve TAK patient refused glucocorticoids and received RTX alone. Clinical evaluation, laboratory tests and imaging modalities (CT or MR-angiography, and 18F-fluorodeoxyglucose PET/CT) were performed at first RTX administration and every 6 months thereafter. Disease activity was assessed using the Kerr index. We also performed a literature review using PubMed, Ovid MEDLINE and Cochrane library. Results. Seven patients (6 females) were included in the study. Mean (S.D.) age was 32.4 (17.3) years. At first RTX administration, all patients had active disease according to the Kerr index (≥), and had also evidence of active disease at PET/CT. Despite RTX treatment, four of the seven patients had evidence of persistent disease activity and/or radiographic disease progression during follow-up. Three out of seven patients in whom RTX was employed as rescue therapy achieved complete remission. In the literature review, we identified five papers describing nine patients treated with RTX with good results in eight cases, but short follow-up. Conclusion. Our data do not support a role for RTX as first line biologic therapy in TAK patients, but it may have a role in some patients as second or third line biologic therapy.
2018
57
7
1151
1155
Rituximab therapy for Takayasu arteritis: A seven patients experience and a review of the literature / Pazzola, Giulia; Muratore, Francesco; Pipitone, Nicolò; Crescentini, Filippo; Cacoub, Patrice; Boiardi, Luigi; Spaggiari, Lucia; Comarmond, Cloe; Croci, Stefania; Saadoun, David; Salvarani, Carlo. - In: RHEUMATOLOGY. - ISSN 1462-0332. - 57:7(2018), pp. 1151-1155. [10.1093/rheumatology/kex249]
Pazzola, Giulia; Muratore, Francesco; Pipitone, Nicolò; Crescentini, Filippo; Cacoub, Patrice; Boiardi, Luigi; Spaggiari, Lucia; Comarmond, Cloe; Croc...espandi
File in questo prodotto:
File Dimensione Formato  
kex249.pdf

Open access

Tipologia: Versione pubblicata dall'editore
Dimensione 123.16 kB
Formato Adobe PDF
123.16 kB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

Licenza Creative Commons
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11380/1155202
Citazioni
  • ???jsp.display-item.citation.pmc??? 12
  • Scopus 55
  • ???jsp.display-item.citation.isi??? 43
social impact